TG2 Inhibitor Compounds for Neurological Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as Alzheimer's, Parkinson's, and Huntington's, and malignancies like glioblastomas, lung, and breast cancers lack effective inhibitors for transglutaminase TG2, which is implicated in these conditions due to its aberrant activity.
Innovation Solution
Development of specific compounds, such as those described in Formula I, which are transglutaminase TG2 inhibitors, capable of inhibiting TG2 activity, thereby providing a therapeutic approach for these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transglutaminase TG2 inhibitors are developed for treating neurological disorders and malignancies, then therapeutic effectiveness is improved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent systematically varies chemical parameters (substituents R1-R6, groups A-B, and structural configurations) to optimize TG2 inhibition while managing compound complexity. By establishing structure-activity relationships and identifying key pharmacophore elements, the invention navigates the trade-off between therapeutic effectiveness and synthetic complexity.
Solution Approach 2:
The patent develops a universal inhibitor framework (Formula I) that can target TG2 across multiple disease states including neurological disorders and malignancies. This multi-functional approach allows a single structural class to address various therapeutic indications, reducing the need for entirely separate compound development programs.
2Reliability
If specific TG2 inhibitor compounds are synthesized and tested, then inhibition efficacy is improved, but manufacturing complexity and time consumption increase
Solution Approach 1:
The patent divides the inhibitor structure into distinct segments (core scaffold A, substituent groups B, R1-R6 positions) that can be independently optimized and synthesized. This modular segmentation enables parallel development of multiple compounds and simplifies the synthesis process by allowing systematic variation of individual moieties.
Solution Approach 2:
The patent identifies and optimizes key pharmacophore elements and structure-activity relationships in advance, establishing a foundation that accelerates subsequent compound development. By performing preliminary structural analysis and activity assessment, the invention reduces the time required for later-stage optimization and clinical development.
Data Source
AI summary
Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.